Breaking AI & Tech News Analyzed

The United States House of Representatives has passed a resolution to rein in President Donald Trump’s powers to attack Iran without congressional authorization. This marks a significant moment of legislative pushback against the administration's military strategy.The Breakthrough Vote: A Rare Bipartisan RejectionIn a decisive 215-208 vote on Wednesday, four Republicans joined Democrats to pass the bill, signaling a rare moment of bipartisan unity against the executive branch's war powers.215-208 Vote: The final tally reflects a narrow but significant majority.Defector Republicans: Tom Barrett of Michigan, Warren Davidson of Ohio, Brian Fitzpatrick of Pennsylvania, and Thomas Massie of Kentucky broke ranks.Historic First: This is the first time this year the House has successfully passed a war powers resolution targeting Trump.The Economic and Strategic Cost of the ConflictThe passage of the resolution comes amid mounting concerns regarding the financial and logistical toll of the ongoing war, which began on February 28 without a formal declaration of war.Financial Impact: The Pentagon estimates the war has cost $29bn, though some analysts project the total could exceed $1tn.Munition Shortages: Critical supplies are depleting faster than anticipated, including Tomahawk missiles, THAAD systems, and PrSMs.Casualty Toll: The conflict has resulted in over 3,400 deaths in Iran and 13 US soldier deaths.Constitutional Friction and Political FalloutThe vote highlights deep constitutional tensions regarding the separation of powers and the specific role of Congress in declaring war.Constitutional Authority: Lawmakers argue that the Constitution exclusively grants the power to declare war to Congress, not the executive branch.Political Retribution: Thomas Massie, a key supporter of the bill, was defeated in his primary by a Trump-backed opponent, highlighting the personal risks for Republicans who defy the President.Public Disapproval: A poll from the Marist Institute found 60% of US citizens disapprove of Trump's handling of the war, a rise from 54% in March.The Veto Hurdle and Future ProspectsWhile the House has spoken, the path to ending the war powers remains obstructed by the executive branch.Senate Pathway: The resolution now moves to the Senate, which previously passed a similar bill in May.Presidential Veto: President Trump is expected to veto the measure, viewing it as an infringement on his authority.Override Threshold: To become law, the bill would need to overcome a veto with a two-thirds majority in both the House and Senate, a threshold neither version has currently breached.

The Lead: A New Voice in American PoliticsDr. Adam Hamawy, an Egyptian-born plastic surgeon and US Army veteran, has secured the Democratic primary for New Jersey’s 12th Congressional District. His victory places him on a direct path to the US House of Representatives, bringing a unique perspective shaped by extensive medical work in global conflict zones, most recently in Gaza during the 2024 conflict.A Surgeon's Transition from Conflict Zones to the Ballot BoxHamawy's pivot to politics was born out of frustration with the legislative branch's response to foreign conflicts. After returning from a medical mission in Gaza, he traveled to Washington, DC, to testify before lawmakers about the realities on the ground. He described a mixed reception, noting that while some lawmakers were receptive, others privately condemned the violence but took no public action, and some refused to meet with him entirely.This legislative inertia prompted his congressional bid. Hamawy's background is deeply rooted in service and crisis response:Military Service: Served as a combat surgeon in Iraq, where he famously saved the life of Senator Tammy Duckworth in 2004 after her helicopter was shot down.Global Medical Missions: Provided medical care in Bosnia, Sudan, Haiti, Lebanon, and Syria.Gaza Experience: Treated patients severely maimed by attacks, an experience he described as enduring relentless bombardment and overwhelming stress.The Shifting Landscape of Progressive Campaign FundingHamawy’s primary victory underscores a shifting dynamic in Democratic politics, particularly regarding US foreign policy in the Middle East. His campaign successfully capitalized on progressive momentum and high-profile endorsements:Key Endorsements: Received backing from Senator Tammy Duckworth and progressive stalwart Senator Bernie Sanders.Financial Backing: Benefited from millions in advertising spending by American Priorities, a pro-Palestinian super PAC.Despite this momentum, the final stretch of the primary was not without friction. Hamawy faced scrutiny over past ties to Omar Abdel-Rahman, a New Jersey Muslim leader convicted in 1995. Hamawy, who has never been accused of any wrongdoing, firmly dismissed the scrutiny, declaring that the era of winning elections through racist and anti-Muslim attacks is over.Disrupting the Congressional Discourse on GazaIf elected in November, Hamawy will become the only member of Congress with recent, firsthand experience inside Gaza. The US Congress plays a pivotal role in the region, controlling billions in annual military aid to Israel and holding the power to block arms transfers.Currently, congressional insight into the enclave is severely limited. No sitting member of Congress is known to have visited Gaza in recent years. The last known visit beyond coordinated border crossing trips was by Keith Ellison in 2013. Since the events of October 7, 2023, outside access has been heavily restricted. Hamawy’s presence in the House would inject direct, eyewitness testimony into legislative debates regarding US military aid and humanitarian funding, which has been further complicated by the shuttering of USAID and the withdrawal of support for UNRWA.Outlook for the November General ElectionHamawy will face Republican Gregg Mele in the midterm elections on November 3. Given that New Jersey’s 12th Congressional District is widely recognized as a Democratic stronghold, Hamawy enters the general election as the heavy favorite. His victory would not only maintain the district's Democratic representation but also signal a broader willingness within the party to elevate candidates who openly challenge the traditional US consensus on the Israeli-Palestinian conflict.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

The Lead From blacklists for UK passport holders to being asked to work illegally while on holiday, the plethora of extra costs and red tape thrown up post-Brexit are restricting opportunities for British actors seeking work in the EU. Mainland Europe has always been a springboard for those in the creative industries, from gaining crucial first credits on a TV, film or theatre production to building a marketable resume and paying the bills while attempting to make it big in the UK or US. The New Barriers for UK Performers Since Brexit, new barriers that have had a devastating effect for performers include visa rules that only allow work for up to 90 out of 180 days, inclusive of any European holiday time, and myriad customs, tax and other documents that can take an inordinate amount of time and cost to get processed, and can vary between countries. The performers' union Equity cited one common example of a member being taxed on their accommodation costs because that was classified as a "benefit in kind", which had a big impact on their net wages. Spotlight pointed out that, for UK performers, social security costs are deducted in the country where they are working – anywhere from 12% to 22% of their pay. This can be reclaimed but the process can take many months, and often requires paying accountants to chase the money. The Decline in European Opportunities Between 2016 and 2023, performing arts exports to the EU fell from £1.15bn to £929m, according to the Office for National Statistics. By contrast, figures for creative industry exports to non-EU countries show an 18% increase over the same period, from £1.57bn to £1.87bn. The National Theatre halted tours to mainland Europe in 2021 and Europe's largest educational touring company, White Horse Theatre, which has provided English-language performances to schools and theatres across Europe for almost half a century, said last year that Brexit threatened its future. In evidence provided to an investigation being conducted by the culture select committee on the impact of Brexit on performers going to the EU, Spotlight said that jobs on TV commercials were now "almost completely unavailable to UK performers". The Impact on Different Segments of the Industry While performers with star status continue to have a streamlined experience, it is jobbing actors who are often finding they are no longer on the list for parts. One past regular source of work was in adverts filmed abroad, such as the long-running "Get away!" campaign for the now defunct package holiday pioneer Lunn Poly, which featured British tourists filmed in locations such as the Balearic islands. In its written evidence sourced from the experiences of its members, Spotlight said it was "aware of named holiday companies that no longer audition UK-only passport holders" to appear in adverts filmed in the bloc. The difficulty for performers also extends to the many other crew involved. One casting director said that, pre-Brexit, one TV campaign employed 45 people based in the UK but similar campaigns are now being cast from Spain or another EU country. The paperwork involved, and the quick-turnaround nature of shooting, has meant that it is simply easier to not bother auditioning UK talent. The Growing Crisis for Emerging Talent It is young UK performers, and in particular those from a working-class background, who have been most hit by the loss of the EU for work and experience. Students and new graduates would previously have typically secured summer contracts for theme parks, tours and cruises, which are now largely closed off post Brexit because of factors such as the visa changes. According to Spotlight, casting directors have seen a significant decrease in working-class actors in particular picking up jobs in the EU. Unlike actors from wealthier backgrounds, who have access to finances to cover things such as visa costs and sometimes having to wait many months for payments relating to working in mainland Europe, they simply cannot afford to accept a job in the EU. The Future Outlook for UK Performers Agents have turned to encouraging actors to check their heritage to see if they are eligible for some form of dual citizenship, an Irish passport, for example, while some businesses based in the EU now actively blacklist UK-only passport holders. However, the "most concerning" anecdotal evidence is of UK performers being asked to skip getting a legitimate work visa if the paperwork can't be finalised in time, and to lie and work while claiming to be on holiday. Spotlight calls this practice a "ticking timebomb" that could involve the use of sanctions for performers and agents caught taking this route to secure work. The agency said this would include "deportation and potential blacklisting" from future opportunities. "The simple answer is Brexit has been catastrophic for the creative industries," says Jonathan Shalit, founder of InterTalent Rights Group. "We as a country made the decision to leave Europe. This is self-inflicted. Europe don't really want us unless they have to."

Wembanyama Guides Spurs to Historic NBA Finals AppearanceVictor Wembanyama entered the 2026 postseason under intense scrutiny about his durability and ability to handle a deep playoff run. By leading the San Antonio Spurs to a Game 7 victory over the Oklahoma City Thunder and securing a spot in the NBA Finals, he proved that his slender frame can withstand the rigors of elite competition. The Spurs’ Playoff Run and Wembanyama’s On‑Court MasteryThe Western Conference finals showcased a blend of poise and explosiveness rarely seen in a player of his stature. Highlights included:Dominant shot‑blocking that turned the glass into a defensive wall.Three‑point shooting from beyond 30 ft, stretching traditional big‑man roles.Ball‑handling and passing comparable to a point guard, creating mismatches.Off the court, Wembanyama displayed a human side—publicly condemning social injustices and sharing personal interests such as chess and Shaolin training—reinforcing his growing cultural influence. Numbers That Highlight Wembanyama’s Unprecedented ProfileAge: 22 years.Height: officially 7ft 4in (some claim up to 7ft 6in).Draft status: No. 1 overall draft pick in 2023.Playoff impact: Led Spurs to their first NBA Finals appearance since 2007. How Wembanyama Is Shaping the Future of the NBAHis skill set forces a reevaluation of the traditional “big man” archetype. Teams now must consider:Recruiting taller players who can also handle the ball and shoot from distance.Designing defensive schemes that account for unprecedented reach and mobility.Marketing narratives that blend athleticism with personal authenticity, as fans respond to his outspoken social stance. What Lies Ahead for Wembanyama and the LeagueLooking forward, the trajectory suggests:Victor Wembanyama could become the face of the NBA’s next branding era, attracting global audiences, especially in Europe.The San Antonio Spurs are likely to build around his unique abilities, influencing roster construction league‑wide.Other franchises may invest in developmental programs that prioritize versatility over sheer bulk, echoing the “Ozempic era” of streamlined athletes.If his health remains intact, the next few seasons could see Wembanyama not only collecting championships but also redefining the positional boundaries of professional basketball.

Lead: Monroe’s Last‑Minute Image Rebellion Marilyn Monroe visited Lawrence Schiller after a nude pool shoot for the unfinished film Something’s Got to Give (1962), cutting up colour negatives she disliked. The episode, recounted by the now‑89‑year‑old photographer, underscores Monroe’s determination to shape her visual legacy. Behind the Pool Shoot: Creative Control in Action May 1962 – Monroe swims in a Hollywood set pool, defying director George Cukor to find better lighting. She jokes, “What if I come out with nothing on?” highlighting her willingness to push boundaries. After the session, she uses scissors to destroy negatives she found unsatisfactory, a gesture Schiller describes as “Ziiiiiip”. Schiller notes that none of the destroyed images were ones he would have published, suggesting Monroe’s edits aligned with professional standards while serving her own vision. Exhibition Data: The National Portrait Gallery Show Opening timed for Monroe’s 100th birthday (early June 2026). Curated by Rosie Broadley, the exhibition frames Monroe as an active director of her image. Features previously unseen pool photographs and commentary from photographers Richard Avedon, Milton Greene, Bert Stern, and Eve Arnold. Impact: Re‑evaluating Monroe’s Cultural Narrative The exhibition challenges the long‑standing myth of Monroe as merely a “messy” blonde bombshell. By foregrounding her “creative agency”, the show invites reassessment of how female stars negotiate studio control, media representation, and personal autonomy. Schiller’s testimony, alongside Arnold’s observations of Monroe’s “lost self”, illustrates a broader pattern: iconic women often reclaim agency through selective image‑making, influencing both contemporary celebrity culture and historical scholarship. Future Outlook: Monroe’s Legacy in the Age of Image Ownership As digital platforms amplify image control, Monroe’s 1962 act of negative‑snipping resonates with modern discussions about artists’ rights and the power of self‑curation. The National Portrait Gallery’s narrative may inspire further exhibitions and academic work that position Monroe alongside today’s media‑savvy figures who dictate how they are seen.

The Looming Public Health Crisis in a Warming UKAs the UK experiences unprecedented record-high May temperatures, a severe inequality is defining how citizens cope with extreme heat. While air conditioning (AC) adoption is surging among the wealthy and healthy, disabled and chronically ill individuals—who face the highest mortality risks during heatwaves—are being systematically priced out of life-saving cooling infrastructure.The Great Cooling DivideThe narrative around British summers has fundamentally shifted from a seasonal novelty to a survival challenge. While 4 million households now boast some form of AC, this statistic masks a grim reality. Affluent homeowners can afford tens of thousands of pounds for built-in cooling systems. In contrast, disabled individuals—who are disproportionately represented in lower-income brackets and rental markets—are left relying on inadequate fans or barred from modifying their rented properties. The ability to regulate body temperature during a heatwave has effectively become a luxury.The Stark Economics of Surviving Extreme HeatThe financial and physical toll of rising global temperatures is quantifiable and deeply alarming. The market is reacting to climate change by squeezing the most vulnerable:4 million: The number of UK households with AC, double the amount from just three years ago.17%: The surge in the cost of AC units in the UK over a single month due to spiking demand.4,500+: The number of excess deaths in Britain during the 2022 heatwave when temperatures exceeded 40C.Infrastructure Inequality and the VulnerableThis crisis extends far beyond private residences. Vulnerable populations residing in care homes, hospitals, schools, and prisons are entirely at the mercy of institutional budgets and government funding. Furthermore, minority ethnic groups and low-income families are disproportionately housed in urban developments prone to dangerous overheating. The current market-based approach to climate adaptation is creating a fatal two-tiered system where marginalized communities are left defenseless against environmental extremes.The Political Weaponization of Climate AdaptationLooking ahead, the failure to provide equitable climate adaptation will trigger not only a public health catastrophe but a severe political crisis. As the physical environment destabilizes, right-wing populists are already leveraging extreme weather to rile public anger against green legislation. Figures such as Nigel Farage and Tony Blair have begun attacking net-zero initiatives and heat pump subsidies. To prevent the political weaponization of the climate crisis, governments must urgently pivot toward systemic solutions: installing AC in public care facilities, creating municipal cool spaces, revolutionizing social housing design, and aggressively reducing emissions to treat the root cause of the warming.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Historic 150th Test at Lord'sLord's Cricket Ground in London is making history this week by hosting its 150th Test match, becoming the first ground in the world to reach this significant milestone. While other venues like Melbourne's MCG follow with 118 Tests, Lord's has maintained its privileged position through hosting two games annually this century. Despite being a late starter to Test cricket (its first match was in July 1884), long after venues like Melbourne, Sydney, The Oval, and Old Trafford, Lord's has cemented its status as cricket's most iconic venue.The Three Lord's of LondonInterestingly, there are actually three Lord's in London. The original ground is now buried under Dorset Square near Marylebone station, while another lies beneath the Lisson Grove moorings on the Regents canal. The current world-famous ground on Wellington Road was rented in the 19th century from the Eyre family, who made their fortune in wine and slavery. This historic patch of land has remained cricket's spiritual home for nearly two centuries.The Cultural Significance of Lord'sDespite its stuffy atmosphere, expensive tickets, and sometimes stifling rules, Lord's holds a special place in cricket lovers' hearts. The venue offers a unique thrill that connects spectators with centuries of cricket history. At Lord's, fans don't just share the game with fellow spectators but with the hundreds of thousands who watched great players before them. Honours boards display heroes' names, museum exhibits showcase their bats, library shelves hold their books, and plaques commemorate their feats.The Evolution of Lord's Cricket GroundLord's wasn't always the established institution it is today. In its early years, the ground held as many pony races and stone-picking contests as cricket matches. The MCC (Marylebone Cricket Club) has faced financial challenges throughout its history, requiring bailouts from wealthier members and even considering building houses on the outfield. The venue has also had to defend against urban encroachment, with red brick walls constructed to guard against the surrounding city and developers attempting to claim the tunnels beneath the ground.Lord's: More Than Just CricketWhile known as the 'Home of Cricket,' Lord's is actually the home of the MCC, a private club that has historically governed the sport. Like Augusta National in golf, it represents a private club running a publicly beloved event. After losing its governing role in 1993, the MCC has been searching for a new identity. Today, it runs charitable programs, hosts special matches, offers tours, and even fields its own professional team in the London Spirit.Five of the Most Memorable Tests at Lord'sEngland v Australia, 1896: England won by six wickets in WG Grace's last Test at Lord's. The crowd was so packed they spilled onto the field, and Australia was skittled for 53 in just 75 minutes on the first morning.England v Australia, 1930: Australia won by seven wickets in Don Bradman's first Test at Lord's. He scored 254, which he later described as 'the best innings of my life'.England v Australia, 1981: Ian Botham's iconic performance with both bat and ball helped England win after following on, one of cricket's greatest comebacks.England v West Indies, 1984: Michael Holding's devastating spell of 6-57 destroyed England, widely regarded as one of the greatest fast bowling performances.England v Australia, 2005: The first Test of the famous Ashes series that ended Australia's reign as world champions, with England's dramatic two-run victory.